KURA Kura Oncology Inc.

Kura Oncology to Participate in Upcoming Investor Conference

Kura Oncology to Participate in Upcoming Investor Conference

SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference.

UBS Virtual Oncology Day

Wednesday, October 1, 2025

2:30 p.m. ET / 11:30 a.m. PT

A live audio webcast will be available in the Investors section of Kura’s website at , with an archived replay available following the event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at and follow us on and .

Contacts

Investors and media:

Greg Mann

858-987-4046



EN
24/09/2025

Underlying

KURAKura Oncology Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kura Oncology Inc.

 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomen...

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology – KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, lines of therapy, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile, including a lack of clinically significant QTc prolongation or myelosuppression – – Prescription Drug Use...

46m 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology to Participate in Upcoming Investor Conference

Kura Oncology to Participate in Upcoming Investor Conference SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in the following investor conference. UBS Virtual Oncology DayWednesday, October 1, 20252:30 p.m. ET / 11:30 a.m. PT A live audio webcast will be available in the Investors section of Kura’s website at , with an archived replay available following the event. ...

September 24, 2025 1 EN
Wedbush Research
  • Wedbush Research
KURA KURA ONCOLOGY INC.
7974 NINTENDO CO. LTD.
ARGX ARGENX ADS
RCUS ARCUS BIOSCIENCES
09/17/25 September 17, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
KURA KURA ONCOLOGY INC.
RCUS ARCUS BIOSCIENCES
09/17/25 September 17, 2025 1 EN
 PRESS RELEASE
Free
KURA Kura Oncology ...

Kura Oncology Highlights Preclinical Data Demonstrating Potential of F...

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 development plans to be presented in October 2025 in conjunction with the ESMO Congress 2025 SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KUR...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch